Darinaparsin-T cell lymphoma-Study

Not Applicable

Recruiting

• Conditions: Peripheral T-cell lymphoma

• Registration Number: JPRN-UMIN000051410
• Lead Sponsor: niversity of Fukui Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-06-22
• Last Update Posted: 17 October 2023
• Study Completion: 2025-06-30

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with QT prolongation on 12-lead ECG (for QT prolongation, QT > 450 msec for males and QT > 470 msec for females; the Fridericia correction formula: QTc=(QT interval)/(RR interval)1/3 should be used to calculate the QT interval). 2) Complicated severe infection. 3) Pregnant or possibly pregnant women. 4) Patients with psychosis or psychiatric symptoms that make it difficult for them to participate in the study. 5) Patients with active multiple cancers (including synchronous multiple cancers, multiple cancers, and iatrogenic multiple cancers with a disease-free interval of less than 5 years. However, even if the disease-free period is less than 5 years, stage I prostate cancer and the following carcinomas that have been completely resected shall not be included in active overlapping or multiple cancers. Gastric cancer (adenocarcinoma): stage 0-I; Colon cancer (adenocarcinoma): stage 0-I; Rectal cancer (adenocarcinoma): stage 0-I; Esophageal cancer (squamous cell carcinoma, adenosquamous carcinoma, basal cell carcinoma): stage 0; Breast cancer (noninvasive ductal carcinoma of breast, noninvasive lobular carcinoma): stage 0; Breast cancer (invasive ductal carcinoma of breast, invasive lobular carcinoma, Paget's disease): stage 0-IIA; Uterine cancer (endometrial adenocarcinoma Stage I), Prostate cancer (adenocarcinoma): Stage I-II, Cervical cancer (squamous cell carcinoma): Stage 0, Thyroid cancer (papillary carcinoma, follicular carcinoma): Stage I-III, Renal cell carcinoma (light-displicated renal cell carcinoma, anaplastic renal cell carcinoma): Stage I) 6) Patients with known hypersensitivity to any component of darinaparsin and those who have received darinaparsin in the past. 7) Cases in which the principal investigator or research coordinator determines that the patient is not appropriate to participate in this study.

Study & Design

• Study Type: Observational
• Study Design: Not specified